One Rock Capital Partners Acquires Innophos for $32.00 per Share (~$932M)

Nordic Capital-Led Consortium Acquires Inovalon

November 24, 2021

Healthcare Services

An equity consortium led by Nordic Capital, joined by Insight Partners, 22C Capital and Inovalon founder Keith Dunleavy, completed the acquisition of Inovalon in a take-private transaction. Inovalon stockholders received $41.00 per share in cash as the cloud-based healthcare data and analytics provider is taken private to accelerate product innovation and expand its reach across the healthcare ecosystem.

One Rock Capital Partners Acquires Kankakee Specialty Chemicals Site from BASF (Kensing)

June 1, 2021

Manufacturing

One Rock Capital Partners' affiliate has completed the acquisition of BASF's Kankakee, Illinois manufacturing site and associated specialty-chemicals businesses and established the standalone company Kensing. The newly independent business, led by CEO Serge Rogasik, employs roughly 160–190 people and produces plant-derived specialty ingredients (phytosterols, natural vitamin E, anionic surfactants and esters) serving personal care, food & nutrition, healthcare and agriculture markets.

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

August 31, 2020

Biotechnology

Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.

BioMarin Acquires Inozyme Pharma

May 16, 2025

Biotechnology

BioMarin Pharmaceutical Inc. completed its acquisition of Inozyme Pharma, Inc. in an all-cash transaction valued at approximately $270 million ($4.00 per share). The deal adds Inozyme's late-stage enzyme replacement therapy INZ-701 for ENPP1 Deficiency to BioMarin's enzyme-therapy portfolio and is expected to accelerate development toward potential regulatory approval.

Bain Capital Private Equity Takes Majority Stake in InnovaCare Health

November 19, 2021

Healthcare Services

Bain Capital Private Equity has signed a definitive agreement to acquire a majority stake in InnovaCare Health, a regional leader in integrated and value-based healthcare services. The investment will support InnovaCare's national expansion and accelerate growth of its physician-led, value-based care model; Summit Partners will remain an equity holder and management will retain significant ownership.

Merck Acquires Acceleron Pharma for $11.5 Billion

September 30, 2021

Biotechnology

Merck has entered into a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, representing an approximate total equity value of $11.5 billion. The acquisition brings Acceleron's late-stage sotatercept program (for pulmonary arterial hypertension) and its REBLOZYL portfolio into Merck's cardiovascular pipeline, subject to tender offer completion and customary regulatory approvals.